Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GTPase activating protein 29 (ARHGAP29)
- Target
- ARHGAP29
- Molecular classification
- Enzyme, Regulatory protein, GAP (GTPase activating protein), Other (specifically, a Rho GTPase regulator)
01
Overview
Rho GTPase activating protein 29 (ARHGAP29) is an enzyme that functions as a GTPase-activating protein (GAP) for members of the Rho-family of small GTPases, particularly RhoA, and to a lesser extent, Rac1 and CDC42[1][3]. By accelerating the hydrolysis of GTP, it inactivates these GTPases, regulating actin cytoskeleton assembly, cell shape, migration, proliferation, and invasion[3][2]. It is essential for processes such as endothelial cell function in vascular tubulogenesis and craniofacial development[1]. Genetic defects in ARHGAP29 are linked to nonsyndromic cleft lip/palate, and altered expression is implicated in the prognosis of several cancers, influencing tumor cell motility and invasiveness[1][2]. No approved drugs directly target ARHGAP29, but it is under active investigation as a mechanistic contributor and potential biomarker in oncology and developmental biology[2][3].
- Other names
- ARHGAP29RhoGAP29RHG29_HUMANRho GTPase-activating protein 29
02
Mechanism of action
No drugs directly target ARHGAP29; however, suppression or modulation of its activity can impact RhoA signaling and cytoskeletal dynamics[2].
03
Biological functions
GTPase activator activity (inactivation of Rho-type GTPases such as RhoA, Rac1, CDC42)Regulation of cytoskeleton (actin organization)Regulation of cell motility and migrationRegulation of cell proliferation and invasionBlood vessel tubulogenesisSignal transduction
04
Disease associations
Cancer (including prostate cancer, gastric cancer)Cleft lip and/or palate (craniofacial developmental defects)Potential role in other diseases involving cytoskeletal dysfunction
05
Safety considerations
Modulating ARHGAP29 may disrupt normal cytoskeletal dynamics and vascular development; loss or overexpression can impact tissue integrity and development[1][2]
06
Biomarkers
Potential prognostic biomarker for prostate cancer and possibly other cancers where ARHGAP29 expression influences cell migration or invasion[2]
Beyond the preview
Go deeper on Rho GTPase activating protein 29 (ARHGAP29).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rho GTPase activating protein 29 (ARHGAP29).